FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and can be used in medicine. Presented is a method for immunotherapy of various proliferative diseases involving administering to a subject a combination of an IL-2 conjugate with DBCO-PEG and an anti-PD-1 antibody. Materials of the present application demonstrate the advantage of using the IL-2 conjugate in combination with a PD-1 inhibitor for treating cancer as compared to using said therapeutic agents separately.
EFFECT: disclosed are types of immuno-oncological combination therapy using il-2 conjugates.
18 cl, 27 dwg, 35 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTERLEUKIN 10 CONJUGATES AND APPLICATIONS THEREOF | 2020 |
|
RU2829811C1 |
| IL-2 CONJUGATES AND METHODS OF USE THEREOF | 2020 |
|
RU2829327C2 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| FIMH ESCHERICHIA COLI MUTANTS AND USE THEREOF | 2021 |
|
RU2831010C1 |
| BIOLOGICAL MATERIALS FOR MODULATING IMMUNE RESPONSES | 2017 |
|
RU2770060C2 |
| ANTIBODY-DRUG CONJUGATES CONTAINING HERBOXYDIENE-BASED SPLICING MODULATOR, AND METHODS OF USE THEREOF | 2019 |
|
RU2820607C2 |
| THERAPEUTIC USE OF LONG-ACTING TRIPLE AGONIST CONJUGATE HAVING ACTIVITIES ON ALL GLUCAGON/GLP-1/GIP RECEPTORS FOR TREATING LUNG DISEASE | 2020 |
|
RU2829342C1 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| PRODRUG COMPOSITIONS BASED ON CROSS-LINKED HYALURONIC ACID HYDROGEL AND METHODS OF THEIR PRODUCTION | 2018 |
|
RU2812787C2 |
| HUMAN INTERLEUKIN-2 VARIANT OR ITS DERIVATIVE | 2019 |
|
RU2799437C2 |
